Incorporating Radiation Oncology into Immunotherapy: Proceedings from the ASTRO-SITC-NCI immunotherapy workshop

Ariel E. Marciscano, Joshua M. Walker, Heather M. McGee, Michelle M. Kim, Charles A. Kunos, Arta M Monjazeb, Stephen L. Shiao, Phuoc T. Tran, Mansoor M. Ahmed

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined. To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session.

Original languageEnglish (US)
Article number6
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
StatePublished - Jan 29 2018

Fingerprint

Radiation Oncology
National Cancer Institute (U.S.)
Immunotherapy
Radiotherapy
Education
Neoplasms
Drug Approval
Food

Keywords

  • ASTRO
  • Cancer
  • Combinations
  • Immune checkpoint blockade
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Radiation oncology
  • Radiation therapy
  • Radiotherapy
  • SITC

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Incorporating Radiation Oncology into Immunotherapy : Proceedings from the ASTRO-SITC-NCI immunotherapy workshop. / Marciscano, Ariel E.; Walker, Joshua M.; McGee, Heather M.; Kim, Michelle M.; Kunos, Charles A.; Monjazeb, Arta M; Shiao, Stephen L.; Tran, Phuoc T.; Ahmed, Mansoor M.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 6, 29.01.2018.

Research output: Contribution to journalArticle

Marciscano, Ariel E. ; Walker, Joshua M. ; McGee, Heather M. ; Kim, Michelle M. ; Kunos, Charles A. ; Monjazeb, Arta M ; Shiao, Stephen L. ; Tran, Phuoc T. ; Ahmed, Mansoor M. / Incorporating Radiation Oncology into Immunotherapy : Proceedings from the ASTRO-SITC-NCI immunotherapy workshop. In: Journal for ImmunoTherapy of Cancer. 2018 ; Vol. 6, No. 1.
@article{0c0bf7aafa4c48d1899b82c4e4df4ead,
title = "Incorporating Radiation Oncology into Immunotherapy: Proceedings from the ASTRO-SITC-NCI immunotherapy workshop",
abstract = "Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined. To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session.",
keywords = "ASTRO, Cancer, Combinations, Immune checkpoint blockade, Immune checkpoint inhibitors, Immunotherapy, Radiation oncology, Radiation therapy, Radiotherapy, SITC",
author = "Marciscano, {Ariel E.} and Walker, {Joshua M.} and McGee, {Heather M.} and Kim, {Michelle M.} and Kunos, {Charles A.} and Monjazeb, {Arta M} and Shiao, {Stephen L.} and Tran, {Phuoc T.} and Ahmed, {Mansoor M.}",
year = "2018",
month = "1",
day = "29",
doi = "10.1186/s40425-018-0317-y",
language = "English (US)",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Incorporating Radiation Oncology into Immunotherapy

T2 - Proceedings from the ASTRO-SITC-NCI immunotherapy workshop

AU - Marciscano, Ariel E.

AU - Walker, Joshua M.

AU - McGee, Heather M.

AU - Kim, Michelle M.

AU - Kunos, Charles A.

AU - Monjazeb, Arta M

AU - Shiao, Stephen L.

AU - Tran, Phuoc T.

AU - Ahmed, Mansoor M.

PY - 2018/1/29

Y1 - 2018/1/29

N2 - Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined. To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session.

AB - Radiotherapy (RT) has been a fundamental component of the anti-cancer armamentarium for over a century. Approximately half of all cancer patients are treated with radiotherapy during their disease course. Over the two past decades, there has been a growing body of preclinical evidence supporting the immunomodulatory effects of radiotherapy, particularly when combined with immunotherapy, but only anecdotal clinical examples existed until recently. The renaissance of immunotherapy and the recent U.S. Food and Drug Administration (FDA) approval of several immune checkpoint inhibitors (ICIs) and other immuno-oncology (IO) agents in multiple cancers provides the opportunity to investigate how localized radiotherapy can induce systemic immune responses. Early clinical experiences have demonstrated feasibility of this approach but additional preclinical and clinical investigation is needed to understand how RT and immunotherapy can be optimally combined. To address questions that are critical to successful incorporation of radiation oncology into immunotherapy, the American Society for Radiation Oncology (ASTRO), the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI) organized a collaborative scientific workshop, Incorporating Radiation Oncology into Immunotherapy, that convened on June 15 and 16 of 2017 at the Natcher Building, NIH Campus in Bethesda, Maryland. This report summarizes key data and highlights from each session.

KW - ASTRO

KW - Cancer

KW - Combinations

KW - Immune checkpoint blockade

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Radiation oncology

KW - Radiation therapy

KW - Radiotherapy

KW - SITC

UR - http://www.scopus.com/inward/record.url?scp=85041017448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041017448&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0317-y

DO - 10.1186/s40425-018-0317-y

M3 - Article

C2 - 29375032

AN - SCOPUS:85041017448

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 6

ER -